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Unstable angina pectoris (USAP) is a complex condition in which widespread coronary 
inflammatory processes have important implications for clearer understanding of its pathogenesis and 
also its treatment. This study aimed at evaluating the diagnostic as well as prognostic value of serum 
inflammatory markers of pentraxin-3 (PTX-3), Von Willebrand Factor (vWf) and C-X-C Motif 
Chemokine Ligand 13 (CXCL13) in such patients. 
Out of sixty-nine patients, thirty-nine had USAP, thirty had stable angina pectoris (SAP), and 
thirty-nine were healthy controls. For all participants, serum PTX-3, vWf and CXCL13 levels were 
measured using ELISA. For each patient with USAP, the Thrombolysis in Myocardial Infarction 
(TIMI) and the scores of Global Registry of Acute Coronary Events (GRACE) were calculated to 
determine the severity of the disease. We, then, analyzed the relation of PTX-3, vWf and CXCL13 
levels with TIMI and GRACE scores in patients with USAP. 
Serum PTX-3, vWf and CXCL13 levels were significantly higher in USAP group than those in 
either SAP or control groups (p˂0.001). Strong correlation was observed between CXCL13 level and 
TIMI risk score (p=0.019). In receiver operating characteristic (ROC) curves, area under the curve 
(AUC) values of PTX3, vWf and CXCL13 for detection of USAP were 0.755, 0.751, and 0.906, 
respectively.  
The levels of serum PTX3, vWf and CXCL13 increased in patients with USAP. The notable 
correlation implied that CXCL13 might be a sensitive and specific biomarker for the diagnosis of 
USAP as well as its severity. It might also show additional diagnostic values when measured in 
combination with vWf. 
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INTRODUCTION 
 
Ischemic heart diseases include a wide spectrum of 
conditions from asymptomatic ischemia, exertion-
induced angina, and unstable angina pectoris (USAP), 
to acute myocardial infarction (MI). USAP relies on the 
top of this spectrum, causing disability and some risks 
greater than those of chronic stable angina pectoris 
(SAP) but less than those of acute MI.
1
 USAP is very 
common and often quite serious form of acute coronary 
syndrome (ACS); it is one of the most frequent causes 
of hospitalization in the united states - more than 
750,000 hospitalizations annually
2
 from which 70,000 
numbers of patients develop MI
3
 and lead to sudden 
death.
4
 The diagnosis of USAP remains clinical and it 
is based on symptom recognition.
5
 Not surprisingly, 
therefore, its diagnosis varies.  
Risk stratification in the early phase of the USAP 
plays a central role in the management of the disease. 
However, the benefit of newer, more aggressive and 
costly strategies seems to be proportional to the risk of 
adverse clinical events. Different scores are now 
available based on initial clinical history, ECG, and 
laboratory tests that enable early risk stratification on 
admission. The score of Thrombolysis In Myocardial 
Infarction (TIMI) developed with the databases from 
large clinical trials of non-ST elevation-acute coronary 
syndrome (NSTE-ACS).
6
 The TIMI Risk Score 
identifies a gradient of increasing risk for death and 
recurrent ischemic events.
6
 The more recent score of 
Global Registry of Acute Coronary Events (GRACE)
7
 
developed to predict the risk of death in ACS patients. 
Such scoring system precisely predicts cardiovascular 
outcome of patients with ACS.
8
 
Both of the above-mentioned scores developed for 
short-term prognosis: events in hospital for the 
GRACE, and at 14 days for the TIMI score.
9
 However, 
the GRACE risk model has been validated as a 




In USAP, a relatively small erosion or fissuring of 
an atherosclerotic plaque may lead to both an acute 
change in plaque structure and a reduction in coronary 
blood flow resulting in exacerbation of angina.
11
 
Inflammatory mediators are intimately associated with 
the cascade of events leading to atherosclerotic plaque 
initiation, development, and rupture.
12
 This recognition 
has led to the evaluation of several markers of 
inflammation as potential tools for cardiovascular risk 
prediction among which high sensitivity C-reactive 
protein (hs-CRP) is the most actively studied one. 
Pentraxin-3 (PTX-3), an inflammatory collectin of 
serum, is made by diverse cell types, predominantly 
macrophages and vascular endothelial cells
13
 in 
response to primary pro-inflammatory signals. Due to 
such sources, instead of the liver, PTX3 levels may 
reflect the inflammatory status of the vasculature more 
directly.  
The Von Willebrand Factor (vWf), a multi-meric 
protein of the acute-phase reaction stored in both 
Weibel-Palade bodies of endothelial cells and platelet 
alpha-granules, can be rapidly released at the local 
injured artery. vWf is crucial for both platelet adhesion 
to exposed sub-endothelium and platelet aggregation.
14
 
Increased vWf plasma concentration is the main 
determinant of platelet aggregation
15
 and in this way it 
may have a causative role in acute coronary thrombotic 
events. The release of vWf in USAP reflects both the 
seriousness of the platelet-mediated events and the 
success of anticoagulant treatment.
16
 
One of the homeostatic chemokines, C-X-C Motif 
Chemokine Ligand 13 (CXCL13), is expressed by 
macrophages, the main leukocyte represented within 
atherosclerotic lesions. Therefore, we may conclude a 
prominent dysregulated interference of CXCL13 in 
atherosclerotic lesions
17




In the present study, we investigated the serum 
levels of PTX3, vWf and CXCL13 as diagnostic 
biomarkers of USAP. We also evaluated the prognostic 
value of such serum markers in USAP patients using 
the GRACE and the TIMI risk scoring systems. 
 
PATIENTS AND METHODS 
 
Study Groups 
This study included 69 ACS patients referring to 
emergency department of Kashan University of 
Medicine School. Group 1 consisted of 39 patients with 
USAP who met the following clinical criterion: 
admission with angina pectoris or equivalent ischemic 
discomfort with at least one of three features of (1) it 
occurred at rest (or with minimal exertion), usually 
lasting>10 minutes; (2) it was severe and of new onset 
(i.e., within the prior 4-6 weeks); and/or (3) it occurred 
with a crescendo pattern (i.e., distinctly more severe, 
prolonged, or frequent than before). Groups 2 consisted 
of 30 patients with SAP who presented with chest 
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discomfort and associated symptoms precipitated by 
some activity (running, walking, etc.) with minimal or 
non-existent symptoms at rest or after administration of 
sublingual nitroglycerin. Group 3 consisted of 39 
healthy controls, 16 men and 23 women who 
consecutively underwent coronary angiography (CAG) 
since 1 to 6 months ago for other reasons like 
suspicious stress test, and whose CAG reports were 
normal. Our inclusion criteria for choosing control 
group was based on CAG report which is the best test 
for rolling out the patients suffering from ischemic 
heart disease. 
Exclusion criteria included significant heart disease 
other than coronary artery disease (CAD); congestive 
heart failure stage III/IV NYHA; symptomatic 
hypotension or uncontrolled hypertension; persistent 
clinically significant laboratory abnormalities; 
significant renal and hepatic dysfunction, other 
significant non-cardiac diseases; and addiction. 
 
Study Protocol 
Patients complaining chest pain agreed to 
participate in the study and therefore they were 
physically examined by an emergency physician and 
underwent electrocardiography, then they were taken to 
the chest pain unit. The patients’ in-hospital 
demographic and clinical courses were recorded to 
complete the TIMI and GRACE severity scores.
6,7
 The 
TIMI Risk Score for Unstable Angina (UA) as well as 
Non-ST Elevation Myocardial Infarction (NSTEMI) is 
a simple clinical score for risk assessment composed of 
seven independent indicators [age≥65 years, three or 
more risk factors for coronary artery disease, known 
significant coronary stenosis, ST deviation≥0.5 mm, 
elevated cardiac marker, severe angina symptoms (≥2 
episodes in prior 24 h), use of aspirin in prior 7 days]. 
For each patient, the score is calculated as the simple 
arithmetic sum of the number of risk indicators (range 
0–7).6 GRACE Risk Score contains important 
hemodynamic variables providing a better evaluation of 
the patient’s illness severity. Its clinical, analytical,  
and electrocardiographic assessment allows a global 
risk evaluation of heart attack and/or death using age,  
heart ate, systolic blood pressure, renal function, 
congestive heart failure, ST-segment deviation, cardiac 
arrest, elevated biomarkers of creatinine and 
troponin.
19
The study protocol was conformed to the 
ethical guidelines of the 1975 Helsinki Declaration and 
was approved by ethical local committee (No 
IR.KAUMS.REC.1395.143). Written informed consent 
obtained from all participants. 
 
Biochemical Evaluation 
Venous blood samples of all subjects were collected 
in heparin-containing tubes. At the same time, serum 
was collected by centrifugation at 4°C, and then stored 
at -20°C until the analysis. PTX3, vWf and CXCL13 
serum levels of all participants were determined by 




Descriptive data are expressed as mean±standard 
deviation, median and percentage. Parametric or non-
parametric tests were used according to the normality 
of data. The difference between the groups was 
calculated by Kruskal Wallis and ANOVA test and 
nominal variables were analyzed by chi-square tests. 
The Pearson and Spearman analysis were used to 
correlate the variables. Linear regression analysis was 
performed to verify the correlations obtained between 
the variables. Receiver operating characteristic (ROC) 
curves compared the diagnostic value of each marker. 
A pof<0.05 was accepted as statistically significant. 




The demographic and experimental characteristics 
of the patients and healthy controls are summarized in 
table 1. A significant difference was observed among 
the groups regarding to PTX-3, vWf and CXCL13 
levels (p<0.001). PTX3 and CXCL13 serum levels 
were significantly higher in patients with USAP than 
those in patients with SAP and healthy controls 
(p<0.001); however, no difference was observed 
between patients with SAP and controls regarding to 
PTX3 and CXCL13 levels (p=0.632, p=0.072, 
respectively). vWf levels were significantly higher both 
in the USAP group than those in SAP as well as control 
groups (p<0.001 and p=0.015, respectively) and in SAP 
group than those in healthy controls (p=0.008). 
Regarding asymmetry in age and sex between our 
groups, all analyses were adjusted according to such 
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Table 1. Demographic and experimental characteristics of the stable angina pectoris (SAP),unstable angina pectoris(USAP) 
and healthy group 



















PTX3 (ng/ml) 12.98±7.66 7.06±4.02 6.20±2.67 <0.001*** 
vWF (ng/ml) 135.37±74.57 91.12±51.42 61.47±15.68 <0.001*** 
CXCL13 (ng/ml) 104.22±39.56 56.46±23.48 50.36±13.36 <0.001*** 
* ANOVA test 
 
 
For each patient with USAP, the TIMI and GRACE 
risk scores were calculated at admission time. The 
mean value of TIMI and GRACE risk score was 2.87 
(range: 1–7), and 101.3 (range: 50–237), respectively. 
Linear regression analysis between the GRACE as well 
as TIMI scores and the PTX3, vWf and CXCL13 levels 
of the USAP patients showed that mean levels of PTX3 
(P=0.648), vWf (p=0.268) and CXCL13 (p=0.212) had 
no correlation with GRACE risk scores (Figure 1). 
PTX3 (p=0.571) and vWf (p=0.785) showed no 
correlation with TIMI risk score. Serum levels of 
CXCL13 were positively correlated with TIMI risk 






Figure 1. Correlation of the serum levels of Pentraxin-3 (PTX3), von Willebrand Factor (vWF); and C-X-C motif chemokine 









































50 100 150 200
grace
ptx3 Fitted values
F. Reygan, et al. 
Vol. 18, No. 2, April 2019                                                                                                                                                            Iran J Allergy Asthma Immunol/204 
Published by Tehran University of Medical Sciences (http://ijaai.tums.ac.ir) 
 
 
Comparing the specificity and sensitivity of PTX3, 
vWf and CXCL13 for the diagnosis of USAP, we 
defined the receiver operating characteristic (ROC) 
curves (Figure 2). Sensitivity and specificity of 
CXCL13 for early diagnosis (after 48 hours) of USAP 
appears to be higher than those of PTX3 and vWf. Area 
under curve (AUC) values for PTX3, vWf and 
CXCL13 were 0.755, 0.751, and 0.906, respectively. 
The best cut-off value for the diagnosis of USAP was 
investigated by ROC analysis (Figure 3). Sensitivity, 
specificity, positive predictive value (PPV), and 
negative predictive value (NPV) of each parameter for 
the diagnosis of USAP were calculated (Table 2). The 
results showed that 66.9 ng/mLwas the optimal plasma 
CXCL13 cut-off value for diagnosis of USAP, and its 
sensitivity, specificity, PPV, and NPV were 0.87, 0.77, 
0.68, and 0.914, respectively. We, furthermore, 
explored the correlation among these biomarkers and 
calculated sensitivity, specificity, positive predictive 
value (PPV), and negative predictive value (NPV) of 
paired parameter for the diagnosis of USAP. 
Circulatory CXCL13 levels showed significant 
correlation with vWf levels and the combination of 
CXCL13 and vWf levels was the most specific 
indicator of USAP. The specificity of such combination 
appears to be higher than those of each PTX3 and vWf 
alone, but less than CXCL13. Area under curve (AUC) 
value for combination of CXCL13 and vWf was 0.786 
and its sensitivity, specificity, PPV, and NPV were 
0.61, 0.95, 0.88, and 0.81, respectively. 
 
 
     A                                            PTX3B                                                                                         VWFC                           
 
CXCL13 
Figure 2. Comparison of ROC curves for diagnosis of unstable angina pectoris at cut point among markers of pentraxin-3 
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Table 2. Optimal cut-off values of the markers for diagnosis of Unstable Angina Pectoris, and their sensitivity, specificity, 
Positive Predictive Value (PPV), and Negative Predictive Value (NPV) 
VWF+CXCL PTX3+CXCL PTX3+VWF CXCL13 vWf PTX3 Classification variables 
91.75±66.90 12.95±66.90 12.95±91.75 66.90 91.75 12.95 Empirical optimal cut point 
0.61 0.46 0.41 0.87 0.68 0.54 Sensitivity at cut point 
0.95 0.97 0.97 0.77 0.79 0.94 Specificity at cut point 
0.786 0.716 0.691 0.82 0.74 0.74 Area under ROC curve at cut point 
0.88 0.90 0.88 0.68 0.65 0.84 Positive Predictive Value 
0.81 0.76 0.74 0.914 0.818 0.783 Negative Predictive Value 




Figure 3. Comparison of ROC curves for diagnosis of unstable angina pectoris among markers of pentraxin-3 (PTX3), von 





In the present study, we have uncovered a hitherto 
unknown role for the PTX3, vWf and CXCL13 in the 
diagnosis of USAP. Many biomarkers are being used 
and tested to stratify the risk of USAP. Although 
cardiac troponins have high sensitivity in the diagnosis 
of myocardial injury, an elevation in their levels may 
be observed in other situations other than cardiac 
events.
20
In light of these discrepancies, new biomarkers 
are required and there exists a need to establish an 
assay system to predict USAP.  
PTX3 is structurally related to classic pentraxins 
such as C-reactive protein (CRP). Although PTX 3 is in 
the same family with CRP, its expression pattern is 
more tissue specific, especially in light of the fact that 
it is expressed in cells of atherosclerotic lesions.
21
 
PTX3 is actually recognized as the vascular CRP
22
 and 
unlike CRP, it is an independent factor among 
conventional risk factors such as diabetes, smoking, 
and hypertension.
23
 On vascular system, PTX3 
enhances the expression of Tissue Factor on endothelial 
cells which potentially plays a role in thrombogenesis 
and ischemic vascular disease.
24
 
Similar to ours, many studies have determined the 
clinical value of PTX3 levels in different cardiac 
pathologies. PTX3 was found in hypertrophied human 
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 PTX3, in 
combination with Troponin T, is a sensitive and 
specific biomarker for the diagnosis of ACS in such a 
way that the more levels of such marker, the more its 
diagnostic value.
26
 Elevated serum PTX-3 levels were 
related to USAP, STEMI, NSTEMI, cardiac failure, 
and cardiovascular events.
27
 A significantly higher 
PTX-3 levels were determined in patients with cardiac 
syndrome X.
28
 PTX3 level might also be a good 
diagnostic tool for predicting outcomes after 
percutaneous coronary intervention in SAP patients.
29
 
In many other studies conducted on patients with 
vascular diseases, mortality was correlated to elevated 
PTX-3 levels.
30
 For instance, in the study by Latini et 
al,
31
 elevated PTX-3 levels have been suggested to be 
related to 3-month mortality in patients with MI. 
Similar to PTX3, high levels of vWf has frequently 
been reported to be linked with cardiovascular 
diseases.
32
In this way, both CRP and vWf may be 
added to the list of useful markers for early detection of 
ACS.
33
 Mechanistically, the vWf intermediates platelet 
adhesion to sites of vascular damage via the 
glycoprotein-Ib receptor, acting as a platelet agonist. It 
also binds to glycoprotein-IIb/IIIa receptor, facilitating 
platelet aggregation.
14
 Moreover, vWf is bound to 
factor VIII to be protected from inactivation, then it 
could be delivered to damaged sites of the vessel.
34
 The 
more vWf, the more factor VIIIa available for both Xa 
and thrombin generation. Such generation plays a 
pivotal role in the thrombotic process.
35
 Translation of 
the above-mentioned pathophysiology to clinic may 
reveal both the predicting value of high plasma levels 
of vWf as an independent risk factor for cardiovascular 
diseases
36
 and the possibility of vWfantagonization in 
overcoming some limitations in the treatment of 
thromotic events.
37
In line with other studies, we 
showed more serum vWf levels in USAP patients. The 
1-year follow-up of the French population enrolled in 
the ESSENCE (Efficacy and Safety of Subcutaneous 
Enoxaparin in Non–Q-Wave Coronary Events)trial 
demonstrated that the combined evaluation of vWf and 
troponin I during the first 48 hours provides useful 
information on long-term prognosis of these patients 
with USAP.
38
 It was reported the predictive value of an 
early rise of vWf for adverse outcomes at one-month in 
USAP patients recruited in a sub-study of the 
ESSENCE trial.
39
 A rise of vWf over the first 48 hours 




Considering the newly recognized role of 
homeostatic chemokines in atherosclerosis,
41
 it was 
hypothesized in our study that CXCL13 could be 
involved in the development of USAP. Such concept 
has also been investigated by little studies. For 
example, in the study by Smedbakken et al, the 
systemic as well as lesioned levels of CXCL13 showed 
an increase in carotid and coronary atherosclerosis 




Although, like ours, several studies have showed an 
elevated serum levels of PTX3, vWf and CXCL13, 
prognostic values of such biomarkers for USAP have 
not yet been fully clarified. We, therefore, showed that 
CXCL13 appears to be superior to PTX3 and Vwf in 
early diagnosis of USAP according to TIMI risk score. 
Our study has also compared, for the first time, the 
diagnostic sensitivity and specificity of PTX3, vWf and 
CXCL13 for USAP. Comparison of such factors by 
ROC curve clearly indicated that CXCL13 shows 
higher sensitivity and specificity than PTX3 as well as 
vWf for the diagnosis of USAP. The present study 
offers a powerful role for the diagnosis of USAP 
through measurement of both CXCL13 and vWf serum 
levels with an AUC value of 0.786. In contrast, PTX3 
appeared to exhibit much less diagnostic values when 
measured in combination with vWf and CXCL13. 
According to our study, all combined tests increased 
the specificity of our test to near 0.97.  
The limitation of our study was that our 
measurements were done only at acute phase and there 
were no longitudinal follow-up samples to evaluate 
their changes during the time. This limitation allowed 
just a cross-sectional analysis with only a limited 
robustness. Furthermore, we evaluated the predictable 
utility of PTX3, vWf and CXCL13 in a population of 
patients exclusively with USAP. Considering low 
frequency of USAP in general population [≈6 of every 
10 000 people],
43
 larger studies are warranted in light 
of these results. 
In conclusion, the present study demonstrates the 
diagnostic value of CXCL13, in the early stage, 
superior to those of PTX3 and vWf, and supports its 
measurement for a more specific risk assessment in 
patients with USAP. These points should further be 
explored in prospective multicenter studies with large 
sample sizes in the future. 
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